An open-label, randomized, phase 1b study evaluating the effect of different doses of AMG 706 [motesanib] on the gallbladder in subjects with advanced solid tumors.

Trial Profile

An open-label, randomized, phase 1b study evaluating the effect of different doses of AMG 706 [motesanib] on the gallbladder in subjects with advanced solid tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2011

At a glance

  • Drugs Motesanib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 07 Jun 2011 Results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
    • 18 Aug 2009 Actual end date (1 Mar 2009) added as reported by ClinicalTrials.gov.
    • 18 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top